Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study

Title:Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study

Volume: 21 Issue: 16

Author(s): Jing Xu, Shuhui Tang, Jie Li, Wei Wang, Meihong Wu and Xianbao Zhan*

Affiliation:

• Department of Oncology, Changhai Hospital, The Naval Military Medical University, Shanghai,China

Keywords: Chemotherapy, adverse effect, nausea, vomiting, antiemetic, neurokinin-1 receptor.

Abstract:

Background: Neurokinin-1 receptor antagonists are playing a major advance in Chemotherapy-Induced Nausea and Vomiting (CINV) as powerful prophylactic agents. Therefore, it is significant to find the association between risk factors of patients and CINV so as to adjust the anti-emetic regimens.

Objective: To evaluate the role of Neurokinin-1 Receptor (NK-1R) antagonist in preventing chemotherapy-induced vomiting in the acute and delayed phases following the first cycle of treatment.

Methods: 145 adult patients with various cancers were recruited in Shanghai Changhai Hospital between September 2017 to November 2017, receiving dual or triple antiemetics.

Results: NK-1R antagonist combined with dexamethasone, 5-HT3R antagonist could effectively control delayed- vomiting in patients after Cycle 1 chemotherapy treatment (4.1% vs. 15.6%, P = 0.041<; 0.05). This study also showed that a history of motion sickness was a predictor of chemotherapy-induced vomiting (CINV) (P = 0.023 <; 0.05). In delayed phase a low consumption of alcohol and history of CIV for males were also significantly associated with CINV (P = 0.036 <; 0.05 and P = 0.002 <; 0.05 respectively).

Conclusion: In this study, we found that triple anti-emetic regimen with NK-1R antagonist could effectively prevent the delayed-vomiting than dual agents. Moreover, some risk factors were observed to be associated with CINV in the delayed phase.

Cite this article as:

Xu Jing , Tang Shuhui , Li Jie , Wang Wei , Wu Meihong and Zhan Xianbao *, Neurokinin-1 Receptor Antagonist Can Prevent the Delayed Phase in Patients: A Single Center Retrospect Study, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (16) . https://dx.doi.org/10.2174/1871520621999210104194038